As a result, GLP-1 coverage for medically accepted FDA-approved indications other than obesity is required while access to GLP-1s to treat obesity under Medicaid is currently limited
Comparison of histological skin changes after massive weight loss in post-bariatric and non-bariatric patients
It also gives you a chance to briefly mention your related article on Tirzepatide vs Semaglutide, though the main focus here is on what comes after tirzepatide, not what came before
When the hepatitis C treatments came out in the 2010s, we had similar conversations about how we could afford those very expensive, highly effective medications, and eventually there was enough competition that prices came down, Klebanoff said
For non-diabetic research subjects, fasting glucose normalization was observed within the first 48 weeks of the escalation phase, even before maximum dose was reached
However, if the A1c is 60 mg/mmol, or progressive increase in UACR despite appropriate therapy, eGFR 30% increase in serum creatinine within 3 months of starting SGLT2i, ACEi, or ARB, inability to achieve target BP, or signs/symptoms of another underlying kidney disease, such as glomerulonephritis
